Abstract
Background and Aims: We have shown previously that concentrations of stool decay-accelerating factor (DAF; CD55), a complement regulatory protein, in patients with ulcerative colitis (UC) are increased in relation to the severity of the colonic mucosal inflammation. In the present study, we evaluated the usefulness of stool DAF as a marker for monitoring disease activity in patients with steroid-resistant active UC being treated with leukocyte apheresis performed with a centrifugal cell separator. Methods: Twenty-one patients with active and steroid-resistant UC were treated with leukocyte apheresis once a week for 4 weeks, and stool DAF concentrations were determined weekly by immunoassay. Results: After treatment, 11 (52%) of the 21 UC patients went into remission. Stool DAF concentrations decreased promptly and steadily in the responsive group. The difference reached statistical significance as soon as after the second apheresis session (P <0.003), compared with values before the therapy and corresponding values in the non-responsive group (P = 0.024). The reduction in stool DAF concentrations after the second apheresis session was significantly greater in the responsive group (median 90%, range 22-90%) than in the non-responsive group (median -13%, range -307-94%) (P = 0.008). Hematological tests, that is, white blood cell (WBC) count and C-reactive protein, declined significantly during the apheresis therapy, but not in relation to therapeutic response. Conclusion: Stool DAF concentration is a useful marker in the clinical response of UC patients to treatment with leukocyte apheresis.
| Original language | English |
|---|---|
| Pages (from-to) | 73-78 |
| Number of pages | 6 |
| Journal | Journal of Gastroenterology and Hepatology (Australia) |
| Volume | 20 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2005 |
Fingerprint
Keywords
- CD55
- Decay-accelerating-factor
- Leukocyte apheresis
- Ulcerative colitis
ASJC Scopus subject areas
- Gastroenterology
- Hepatology
Cite this
Stool decay-accelerating factor as a marker for monitoring the disease activity during leukocyte apheresis therapy in patients with refractory ulcerative colitis. / Kohno, Hiroyuki; Mizuno, Motowo; Nasu, Junichirou; Makidono, Chiho; Hiraoka, Sakiko; Inaba, Tomoki; Yamamoto, Kazuhide; Okada, Hiroyuki; Fujita, Teizo; Shiratori, Yasushi.
In: Journal of Gastroenterology and Hepatology (Australia), Vol. 20, No. 1, 2005, p. 73-78.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Stool decay-accelerating factor as a marker for monitoring the disease activity during leukocyte apheresis therapy in patients with refractory ulcerative colitis
AU - Kohno, Hiroyuki
AU - Mizuno, Motowo
AU - Nasu, Junichirou
AU - Makidono, Chiho
AU - Hiraoka, Sakiko
AU - Inaba, Tomoki
AU - Yamamoto, Kazuhide
AU - Okada, Hiroyuki
AU - Fujita, Teizo
AU - Shiratori, Yasushi
PY - 2005
Y1 - 2005
N2 - Background and Aims: We have shown previously that concentrations of stool decay-accelerating factor (DAF; CD55), a complement regulatory protein, in patients with ulcerative colitis (UC) are increased in relation to the severity of the colonic mucosal inflammation. In the present study, we evaluated the usefulness of stool DAF as a marker for monitoring disease activity in patients with steroid-resistant active UC being treated with leukocyte apheresis performed with a centrifugal cell separator. Methods: Twenty-one patients with active and steroid-resistant UC were treated with leukocyte apheresis once a week for 4 weeks, and stool DAF concentrations were determined weekly by immunoassay. Results: After treatment, 11 (52%) of the 21 UC patients went into remission. Stool DAF concentrations decreased promptly and steadily in the responsive group. The difference reached statistical significance as soon as after the second apheresis session (P <0.003), compared with values before the therapy and corresponding values in the non-responsive group (P = 0.024). The reduction in stool DAF concentrations after the second apheresis session was significantly greater in the responsive group (median 90%, range 22-90%) than in the non-responsive group (median -13%, range -307-94%) (P = 0.008). Hematological tests, that is, white blood cell (WBC) count and C-reactive protein, declined significantly during the apheresis therapy, but not in relation to therapeutic response. Conclusion: Stool DAF concentration is a useful marker in the clinical response of UC patients to treatment with leukocyte apheresis.
AB - Background and Aims: We have shown previously that concentrations of stool decay-accelerating factor (DAF; CD55), a complement regulatory protein, in patients with ulcerative colitis (UC) are increased in relation to the severity of the colonic mucosal inflammation. In the present study, we evaluated the usefulness of stool DAF as a marker for monitoring disease activity in patients with steroid-resistant active UC being treated with leukocyte apheresis performed with a centrifugal cell separator. Methods: Twenty-one patients with active and steroid-resistant UC were treated with leukocyte apheresis once a week for 4 weeks, and stool DAF concentrations were determined weekly by immunoassay. Results: After treatment, 11 (52%) of the 21 UC patients went into remission. Stool DAF concentrations decreased promptly and steadily in the responsive group. The difference reached statistical significance as soon as after the second apheresis session (P <0.003), compared with values before the therapy and corresponding values in the non-responsive group (P = 0.024). The reduction in stool DAF concentrations after the second apheresis session was significantly greater in the responsive group (median 90%, range 22-90%) than in the non-responsive group (median -13%, range -307-94%) (P = 0.008). Hematological tests, that is, white blood cell (WBC) count and C-reactive protein, declined significantly during the apheresis therapy, but not in relation to therapeutic response. Conclusion: Stool DAF concentration is a useful marker in the clinical response of UC patients to treatment with leukocyte apheresis.
KW - CD55
KW - Decay-accelerating-factor
KW - Leukocyte apheresis
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=19944433620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19944433620&partnerID=8YFLogxK
U2 - 10.1111/j.1440-1746.2004.03545.x
DO - 10.1111/j.1440-1746.2004.03545.x
M3 - Article
C2 - 15610450
AN - SCOPUS:19944433620
VL - 20
SP - 73
EP - 78
JO - Journal of Gastroenterology and Hepatology (Australia)
JF - Journal of Gastroenterology and Hepatology (Australia)
SN - 0815-9319
IS - 1
ER -